查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1969411

主动脉瓣狭窄市场：按产品类型、瓣膜材质、年龄层和最终用户划分 - 2026-2032 年全球预测

Aortic Stenosis Market by Product Type, Valve Material, Age Group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，主动脉瓣狭窄市场价值将达到 98.9 亿美元，到 2026 年将成长至 109 亿美元，到 2032 年将达到 199.3 亿美元，年复合成长率为 10.51%。

主要市场统计数据
基准年 2025 98.9亿美元
预计年份：2026年 109亿美元
预测年份 2032 199.3亿美元
复合年增长率 (%) 10.51%

本次演讲将清楚阐述临床技术的进步、人口结构的变化以及手术创新如何重塑所有相关人员。

主动脉瓣狭窄已从单纯的外科手术问题发展成为一个涉及多方面的临床和商业性领域，持续吸引临床医生、医疗设备开发商和医疗保健系统的关注。过去十年，经导管技术的进步、瓣膜设计和生物材料的改进以及手术全期护理路径的完善，都促成了治疗模式的转变。因此，目前的治疗方案在传统外科手术和微创经导管治疗之间取得了平衡，而患者的选择、合併症的管理以及医疗机构的能力也日益影响着手术方案的选择。

技术成熟、手术流程的广泛采用以及支付主导以价值为中心的策略如何汇聚起来，从根本上改变主动脉瓣狭窄治疗的临床实践和商业策略？

近年来，主动脉瓣狭窄治疗领域发生了变革性变化，这源于技术的成熟、手术模式的演变以及相关人员期望的不断提高。尤其值得注意的是，随着医疗机构不断优化患者分诊和心臟团队工作流程，经导管介入治疗的兴起。持续改进的器械进一步强化了这一趋势，这些器械解决了瓣週漏、起搏器使用率和输送系统特性等挑战。同时，对于某些解剖结构、年轻患者以及合併复杂疾病的患者，外科主动脉瓣置换术仍然至关重要。这两种治疗方法并存，需要在临床和商业性策略上进行差异化。

对 2025 年美国关税对设备采购、医院采购行为和製造业韧性的营运、采购和策略影响进行多方面分析。

美国2025年实施的关税政策为供应链、定价和采购带来了复杂的变化，对医疗设备製造和医疗服务提供者的采购行为产生了影响。短期来看，关税提高了进口零件和成品阀门系统的到岸成本，迫使製造商重新评估其筹资策略，并加快关键生产过程的近岸外包和本地化。因此，原始设备製造商（OEM）正在评估双重采购协议、认证替代供应商并增加库存缓衝，以降低供应中断的风险。

将手术方法、瓣膜材料、医疗环境和年龄层与设备设计影响、训练需求和采购优先事项连结起来的可操作細項分析。

深入的細項分析揭示了不同手术类型、材料、医疗机构和患者群体在应用模式和临床需求多样性方面的细微差异。依产品类型划分，可区分外科主动脉瓣置换术术和经导管主动脉瓣置换术（TAVR），其中外科手术方法又可根据瓣膜类型进一步分为球囊扩张型和自扩张式。经导管手术方法则进一步细分为经心尖入路和经股动脉路径。经心尖入路包括左前胸切口和左前外侧切口，而经股动脉路径则分为经皮动脉入路和外科经股动脉路径。这些差异会影响器械规格、操作者技能和手术全期计划，从而对培训项目和设备采购决策产生直接影响。

从区域观点深入分析偿还系统、基础设施成熟度和人口趋势如何影响全球技术、商业策略和区域伙伴关係的采用。

主动脉瓣狭窄治疗的临床启动模式、监管预期和商业策略持续受到区域趋势的影响。在美洲，儘管先进技术的应用和高病例量医疗机构的整合正在推进，但支付方主导的严格审查机制依然存在，并高度重视治疗效果和成本效益。这种环境有助于建立持久的、循证的治疗平台和整合式服务模式，从而减少住院时间和再入院风险。同时，在欧洲、中东和非洲，由于各国报销制度的差异、专科医疗机构可及性的不均衡以及监管时间表的不同，情况呈现出显着的多样性，这为开展区域性临床证据宣传活动和与区域分销商建立选择性合作关係创造了机会。

对影响医疗保健领域采购决策和企业差异化的产品平台策略、服务模式和证据生成竞争考察。

主动脉瓣狭窄领域的竞争格局取决于产品改进、真实世界临床证据的累积以及对综合服务模式的持续投入。领先的製造商正致力于平台扩充性，以开发能够适应各种解剖结构、入路和输送系统的瓣膜系列，同时透过独特的组织处理技术、抗钙化技术以及降低手术复杂性的输送导管人体工学设计来实现差异化。除了产品性能之外，企业提供全面的培训、指导和上市后监测的能力也日益受到重视，这些服务能够支援安全部署并优化不同临床环境下的治疗效果。

为经营团队提供切实有效的建议，以加强价值链韧性，加快临床部署，并透过实证伙伴关係向支付方证明价值。

产业领导者应采取整合策略方法，使产品创新与营运实际情况和支付方期望一致。首先，透过供应商多元化、关键零件近岸外包和策略性库存管理，优先提升供应链韧性，既能确保产品按时上市，也能降低关税和地缘政治风险。其次，投资于股动脉入路和复杂外科手术技术的临床培训和系统性指导项目，将加速安全应用，降低治疗结果的差异性，并促使医疗机构更早采用这些技术。

我们采用透明的多来源调查方法，结合临床文献、註册分析和相关人员访谈，提供检验的见解和可靠的策略指导。

本研究整合了临床文献、註册登记资料以及对关键相关人员的访谈，旨在全面了解主动脉瓣狭窄治疗的趋势。调查方法结合了对同行评审的临床研究和指南声明的系统性回顾，以及对手术层面註册登记和器械安全资料库的分析，以捕捉手术趋势和治疗结果征兆。为了补充定量资讯来源，研究人员还对介入性心臟病专家、心臟外科医生、医院采购经理、门诊手术中心管理人员和医疗设备业高管进行了结构化访谈，以检验假设、识别运营限制并了解新兴的临床偏好。

这项简洁而前瞻性的结论强调了产品、临床和商业策略必须保持一致，才能将主动脉狭窄治疗的创新转化为可扩展的改进。

总之，主动脉瓣狭窄的治疗格局呈现出临床创新融合、手术方式偏好转变以及所有相关人员日益关注价值的趋势。外科手术和经导管治疗的相互作用要求製造商和医疗服务提供者采取互补策略，以满足解剖学特征和以患者为中心的需求，同时简化在不同治疗环境中的部署。关税和区域监管差异导致的供应链中断进一步凸显了适应性生产、稳健的供应商管理以及立足本地的商业化规划的重要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 主动脉瓣狭窄市场：依产品类型划分

  • 外科主动脉瓣置换术
  • 经导管主动脉瓣置换术
    • 跨中心方法
      • 左侧前侧小切口开胸术
      • 左侧前外侧小切口开胸术
    • 经股骨入路
      • 经皮股动脉入路
      • 股动脉外科入路

第九章 主动脉瓣狭窄市场（依瓣膜材质划分）

  • 生物瓣膜
    • 源自牛
    • 源自猪
  • 机械阀
    • 笼球
    • 倾斜盘

第十章：主动脉瓣狭窄市场：依年龄组别划分

  • 成人版
  • 儿童

第十一章 主动脉瓣狭窄市场：依最终用户划分

  • 门诊手术中心
  • 医院
    • 当地医院
    • 三好医院

第十二章 主动脉瓣狭窄市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 主动脉瓣狭窄市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 主动脉瓣狭窄市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国主动脉瓣狭窄市场

第十六章：中国主动脉瓣狭窄市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 4C Medical Technologies, Inc.
  • Abbott Laboratories
  • AstraZeneca plc
  • B. Braun Melsungen AG
  • Biotronik
  • Boston Scientific Corporation
  • CryoLife, Inc.
  • Edwards Lifesciences Corporation
  • JenaValve Technology, Inc.
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • LifeNet Health
  • LivaNova PLC
  • LivaNova PLC
  • Medtronic plc
  • MicroPort Scientific Corporation
  • Venus Medtech（Hangzhou）Co., Ltd.
Product Code: MRR-535C629188E8

The Aortic Stenosis Market was valued at USD 9.89 billion in 2025 and is projected to grow to USD 10.90 billion in 2026, with a CAGR of 10.51%, reaching USD 19.93 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.89 billion
Estimated Year [2026] USD 10.90 billion
Forecast Year [2032] USD 19.93 billion
CAGR (%) 10.51%

A clear introduction to how clinical advances, demographic shifts, and procedural innovations are reshaping aortic stenosis care pathways and strategic priorities across stakeholders

Aortic stenosis has evolved from a narrowly defined surgical problem to a multifaceted clinical and commercial landscape drawing sustained attention from clinicians, device innovators, and health systems. Over the past decade, advances in transcatheter techniques, improvements in valve design and biomaterials, and refined peri-procedural care pathways have collectively shifted treatment paradigms. As a result, care delivery now balances long-established surgical approaches with less invasive transcatheter options, while patient selection, comorbidity management, and institutional capabilities increasingly dictate procedural choice.

Technological progress has not only expanded therapeutic options but has also altered training needs, capital planning, and procurement behaviors across hospitals and ambulatory centers. Simultaneously, demographic forces-principally population aging and higher prevalence of degenerative valvular disease-are driving sustained demand for durable, safe, and reproducible interventions. Clinicians are focusing on optimizing long-term outcomes through better valve sizing algorithms, imaging-guided implantation, and integrated heart team decision-making, thus tightening the link between device innovation and clinical practice.

Regulatory pathways and reimbursement frameworks continue to adapt to differentiated product profiles and real-world evidence, which reinforces the importance of rigorous clinical data and post-market surveillance. Taken together, these factors create a dynamic environment in which manufacturers, providers, and payers must align clinical value propositions with practical implementation strategies to succeed.

How technological maturation, procedural adoption, and payer-driven value imperatives are converging to fundamentally transform clinical practice and commercial strategy in aortic stenosis care

Recent transformative shifts in the aortic stenosis landscape are rooted in technological maturation, procedural adoption patterns, and evolving stakeholder expectations. The most visible change is the ascendancy of transcatheter approaches as centers refine patient triage and heart-team workflows; this trend has been reinforced by iterative device improvements that address paravalvular leak, pacemaker rates, and delivery system profiles. At the same time, surgical aortic valve replacement remains essential for specific anatomy, younger patients, and complex concomitant procedures, preserving a dual-modality continuum that demands differentiated clinical and commercial strategies.

Material science innovations have promoted the preferential use of biological valve materials in many adult populations while mechanical designs continue to serve niche indications; concurrently, valve architecture choices-such as balloon-expandable versus self-expanding platforms-have created distinct procedural profiles and training requirements. In parallel, value-based care imperatives and payer scrutiny are accelerating the adoption of protocols that shorten length of stay, enable same-day or next-day discharge where appropriate, and measure outcomes through standardized registries. These changes are prompting hospitals and ambulatory surgical centers to reassess capital investments, staff competencies, and vendor partnerships.

Moreover, global supply chain reconfigurations and regulatory harmonization efforts are encouraging manufacturers to invest in modular platform strategies and adaptable service models. As a result, new entrants and incumbent firms are placing greater emphasis on lifecycle management, incremental innovation, and evidence generation to support differentiated positioning in a rapidly evolving competitive arena.

Analyzing the multifaceted operational, procurement, and strategic consequences of United States 2025 tariffs on device sourcing, hospital purchasing behavior, and manufacturing resilience

The imposition of United States tariffs in 2025 has introduced a complex set of supply chain, pricing, and procurement dynamics that ripple across device manufacturing and institutional purchasing practices. In the near term, tariffs have increased the landed cost of imported components and finished valve systems, compelling manufacturers to reassess sourcing strategies and to accelerate nearshoring or regionalization of key production steps. Consequently, original equipment manufacturers are evaluating dual-sourcing agreements, qualifying alternate suppliers, and increasing inventory buffers to mitigate the risk of supply disruptions.

Hospitals and ambulatory surgical centers are responding by tightening procurement negotiations and exploring longer-term contracting to manage price volatility. In some instances, health systems are prioritizing devices with the most predictable total cost of care profiles, placing higher value on durable performance and reduced complication rates that lower downstream costs. Additionally, tariff-related cost pressures have stimulated greater collaboration between clinical teams and supply chain leaders to optimize device selection protocols and to adopt clinically driven standardization where appropriate.

Over time, the tariffs have also acted as a catalyst for strategic investment in domestic manufacturing capacity, leveraging public-private partnerships and targeted incentives. This shift can enhance resilience but may require substantial capital and time to scale. From a regulatory and competitive standpoint, tariffs have prompted more granular supplier qualification criteria and intensified the focus on lifecycle service offerings, training support, and bundled solutions that offset price increases through demonstrable clinical and operational efficiencies.

Actionable segmentation intelligence linking procedural approaches, valve materials, care settings, and age cohorts to device design implications, training needs, and procurement priorities

Insightful segmentation analysis reveals nuanced adoption patterns and differentiated clinical needs across procedural types, materials, care settings, and patient populations. By product type, the field distinguishes surgical aortic valve replacement from transcatheter aortic valve replacement, with surgical approaches further defined by valve type into balloon-expandable and self-expanding designs, while transcatheter therapy is subdivided into transapical and transfemoral approaches; within the transapical category practitioners deploy left anterior mini thoracotomy or left anterolateral mini thoracotomy techniques, and transfemoral access is categorized between percutaneous transfemoral and surgical transfemoral routes. These distinctions influence device specification, operator skill sets, and peri-procedural planning, and they have direct implications for training programs and capital procurement decisions.

Valve material segmentation also matters: biological valves, typically derived from bovine or porcine tissue, offer advantages in hemodynamics and avoid lifelong anticoagulation for many adult patients, whereas mechanical designs such as caged ball and tilting disc valves retain a role in carefully selected populations where durability is paramount. End user segmentation separates ambulatory surgical centers from hospitals; ambulatory centers, often structured as standalone clinics, emphasize throughput, standardized protocols, and rapid recovery pathways, while hospitals-which comprise community and tertiary facilities-manage a broader case mix, complex comorbidities, and integrated multidisciplinary care models. Finally, age group segmentation between adult and pediatric populations requires distinct device sizing, long-term planning, and follow-up strategies that shape both clinical pathways and product development priorities.

Deep regional perspectives on how reimbursement, infrastructure maturity, and demographic trends are influencing procedural adoption, commercial strategies, and local partnerships globally

Regional dynamics continue to shape clinical adoption patterns, regulatory expectations, and commercial strategies in aortic stenosis care. In the Americas, advanced procedural uptake and consolidation of high-volume centers coexist with payer-driven scrutiny that emphasizes outcomes and cost-effectiveness; this environment favors durable, evidence-backed platforms and integrated service models that reduce hospital length of stay and readmission risk. Conversely, Europe, Middle East & Africa exhibits heterogeneity driven by divergent national reimbursement frameworks, variable access to specialized centers, and differing regulatory timelines, which creates opportunities for tailored clinical evidence campaigns and selective partnerships with regional distributors.

In Asia-Pacific, expanding access to minimally invasive interventions, rapid infrastructure development in tertiary hospitals, and substantial investments in training are increasing the adoption of transcatheter therapies, while demographic trends-particularly aging populations in several regional markets-are elevating clinical demand. Across regions, supply chain considerations, tariff policies, and local manufacturing incentives are prompting companies to adapt product strategies and pricing approaches to align with regional procurement norms and institutional capabilities. As a result, successful commercial playbooks increasingly combine global platform consistency with localized training programs, registry participation, and health-economic evidence tailored to regional payer expectations.

Key competitive insights detailing how product platform strategies, service models, and evidence generation are shaping company differentiation and procurement decisions across care settings

Competitive dynamics in the aortic stenosis ecosystem are shaped by sustained investment in product improvement, real-world evidence generation, and integrated service models. Leading manufacturers are concentrating on platform extensibility-developing valve families that accommodate a broad range of anatomies, access routes, and delivery systems-while differentiating through proprietary tissue treatments, anti-calcification technologies, and delivery catheter ergonomics that reduce procedural complexity. In addition to product performance, companies are increasingly judged by their ability to provide comprehensive training, proctoring, and post-market surveillance that support safe adoption and optimize outcomes across diverse clinical settings.

Partnerships between device firms and clinical networks, as well as strategic alliances with imaging and software providers, are expanding the value proposition beyond a single implant to encompass pre-procedural planning, intra-procedural guidance, and longitudinal outcome tracking. Meanwhile, service-oriented offerings such as bundled pricing, outcome-linked contracts, and hybrid warranty models are emerging as competitive differentiators in procurement discussions. New entrants and established players alike must therefore synchronize R&D priorities with scalable manufacturing, robust supply chain governance, and credible evidence programs to sustain long-term commercial momentum.

Practical, high-impact recommendations for executives to strengthen supply chain resilience, accelerate clinical adoption, and demonstrate value to payers through evidence-driven partnerships

Industry leaders should pursue an integrated strategic approach that aligns product innovation with operational realities and payer expectations. First, prioritizing supply chain resilience through supplier diversification, nearshoring of critical components, and strategic inventory management will mitigate tariff-related and geopolitical risks while preserving launch timelines. Second, investing in clinical training and structured proctoring programs for transfemoral and complex surgical techniques will accelerate safe adoption and reduce variability in outcomes, enabling faster institutional buy-in.

Third, developing modular product platforms that accommodate both balloon-expandable and self-expanding principles and that can be optimized for transfemoral and transapical use will lower lifecycle costs and simplify inventory management for purchasers. Fourth, collaborating proactively with payers to demonstrate total cost of care advantages-through registry participation, real-world studies, and bundled care pilots-will support reimbursement discussions and create pathways for value-based contracting. Finally, committing resources to localized market strategies that combine evidence generation, tailored training, and service support will improve market access and stakeholder trust, especially in regions with heterogeneous regulatory and procurement environments.

Transparent, multi-source research methodology combining clinical literature, registry analytics, and stakeholder interviews to deliver validated insights and credible strategic guidance

This research synthesizes clinical literature, registry data, and primary stakeholder interviews to build a comprehensive understanding of aortic stenosis care dynamics. The methodology combines systematic review of peer-reviewed clinical studies and guideline statements with analysis of procedure-level registries and device safety databases to capture procedural trends and outcome signals. Complementing quantitative sources, structured interviews were conducted with interventional cardiologists, cardiac surgeons, hospital procurement leaders, ambulatory surgical center administrators, and device industry executives to validate assumptions, surface operational constraints, and identify emerging clinical preferences.

Data were triangulated using cross-source validation techniques and subject-matter expert adjudication to ensure interpretive fidelity. Segmentation frameworks were mapped against procedural practice patterns, institutional capabilities, and payer landscapes to produce actionable insights. Recognizing limitations, the methodology accounts for regional variability in registry completeness and acknowledges that evolving clinical trials and regulatory decisions may influence practice over time; as such, findings are presented with transparency regarding data vintage, primary sources, and the scope of primary interviews.

A concise, forward-looking conclusion emphasizing the need for aligned product, clinical, and commercial strategies to convert innovation into scalable improvements in aortic stenosis care

In conclusion, the aortic stenosis landscape is defined by converging clinical innovations, shifting procedural preferences, and heightened attention to value across stakeholders. The interplay between surgical and transcatheter therapies requires manufacturers and providers to pursue complementary strategies that address distinct anatomical and patient-centric needs while streamlining implementation in diverse care settings. Tariff-driven supply chain perturbations and regional regulatory variation further underscore the importance of adaptive manufacturing, robust supplier governance, and localized commercialization plans.

Success in this environment will favor organizations that align product design with clinical workflows, invest in evidence and training, and engage payers with credible value propositions. By synthesizing segmentation, regional nuance, and competitive dynamics, leaders can identify targeted opportunities to optimize portfolios, strengthen partnerships, and deliver demonstrable improvements in patient outcomes and operational efficiency. Continued collaboration across clinical, commercial, and policy stakeholders will be essential to translate technological progress into scalable, sustainable care improvements for patients with aortic stenosis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Aortic Stenosis Market, by Product Type

  • 8.1. Surgical Aortic Valve Replacement
  • 8.2. Transcatheter Aortic Valve Replacement
    • 8.2.1. Transapical Approach
      • 8.2.1.1. Left Anterior Mini Thoracotomy
      • 8.2.1.2. Left Anterolateral Mini Thoracotomy
    • 8.2.2. Transfemoral Approach
      • 8.2.2.1. Percutaneous Transfemoral
      • 8.2.2.2. Surgical Transfemoral

9. Aortic Stenosis Market, by Valve Material

  • 9.1. Biological
    • 9.1.1. Bovine
    • 9.1.2. Porcine
  • 9.2. Mechanical
    • 9.2.1. Caged Ball
    • 9.2.2. Tilting Disc

10. Aortic Stenosis Market, by Age Group

  • 10.1. Adult
  • 10.2. Pediatric

11. Aortic Stenosis Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals
    • 11.2.1. Community Hospitals
    • 11.2.2. Tertiary Hospitals

12. Aortic Stenosis Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Aortic Stenosis Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Aortic Stenosis Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Aortic Stenosis Market

16. China Aortic Stenosis Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 4C Medical Technologies, Inc.
  • 17.6. Abbott Laboratories
  • 17.7. AstraZeneca plc
  • 17.8. B. Braun Melsungen AG
  • 17.9. Biotronik
  • 17.10. Boston Scientific Corporation
  • 17.11. CryoLife, Inc.
  • 17.12. Edwards Lifesciences Corporation
  • 17.13. JenaValve Technology, Inc.
  • 17.14. Lepu Medical Technology (Beijing) Co., Ltd.
  • 17.15. LifeNet Health
  • 17.16. LivaNova PLC
  • 17.17. LivaNova PLC
  • 17.18. Medtronic plc
  • 17.19. MicroPort Scientific Corporation
  • 17.20. Venus Medtech (Hangzhou) Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AORTIC STENOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AORTIC STENOSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AORTIC STENOSIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AORTIC STENOSIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AORTIC STENOSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AORTIC STENOSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AORTIC STENOSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES AORTIC STENOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA AORTIC STENOSIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AORTIC STENOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AORTIC STENOSIS MARKET SIZE, BY SURGICAL AORTIC VALVE REPLACEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AORTIC STENOSIS MARKET SIZE, BY SURGICAL AORTIC VALVE REPLACEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AORTIC STENOSIS MARKET SIZE, BY SURGICAL AORTIC VALVE REPLACEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AORTIC STENOSIS MARKET SIZE, BY LEFT ANTERIOR MINI THORACOTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AORTIC STENOSIS MARKET SIZE, BY LEFT ANTERIOR MINI THORACOTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AORTIC STENOSIS MARKET SIZE, BY LEFT ANTERIOR MINI THORACOTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AORTIC STENOSIS MARKET SIZE, BY LEFT ANTEROLATERAL MINI THORACOTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AORTIC STENOSIS MARKET SIZE, BY LEFT ANTEROLATERAL MINI THORACOTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AORTIC STENOSIS MARKET SIZE, BY LEFT ANTEROLATERAL MINI THORACOTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AORTIC STENOSIS MARKET SIZE, BY PERCUTANEOUS TRANSFEMORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AORTIC STENOSIS MARKET SIZE, BY PERCUTANEOUS TRANSFEMORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AORTIC STENOSIS MARKET SIZE, BY PERCUTANEOUS TRANSFEMORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AORTIC STENOSIS MARKET SIZE, BY SURGICAL TRANSFEMORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AORTIC STENOSIS MARKET SIZE, BY SURGICAL TRANSFEMORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AORTIC STENOSIS MARKET SIZE, BY SURGICAL TRANSFEMORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AORTIC STENOSIS MARKET SIZE, BY BOVINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AORTIC STENOSIS MARKET SIZE, BY BOVINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AORTIC STENOSIS MARKET SIZE, BY BOVINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AORTIC STENOSIS MARKET SIZE, BY PORCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AORTIC STENOSIS MARKET SIZE, BY PORCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AORTIC STENOSIS MARKET SIZE, BY PORCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AORTIC STENOSIS MARKET SIZE, BY CAGED BALL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AORTIC STENOSIS MARKET SIZE, BY CAGED BALL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AORTIC STENOSIS MARKET SIZE, BY CAGED BALL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TILTING DISC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TILTING DISC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TILTING DISC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AORTIC STENOSIS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AORTIC STENOSIS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AORTIC STENOSIS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AORTIC STENOSIS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AORTIC STENOSIS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AORTIC STENOSIS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AORTIC STENOSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AORTIC STENOSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AORTIC STENOSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AORTIC STENOSIS MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AORTIC STENOSIS MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL AORTIC STENOSIS MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TERTIARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TERTIARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AORTIC STENOSIS MARKET SIZE, BY TERTIARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL AORTIC STENOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS AORTIC STENOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA AORTIC STENOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA AORTIC STENOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA AORTIC STENOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE AORTIC STENOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST AORTIC STENOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA AORTIC STENOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC AORTIC STENOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL AORTIC STENOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN AORTIC STENOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 173. GCC AORTIC STENOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GCC AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. GCC AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 176. GCC AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 177. GCC AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 178. GCC AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 179. GCC AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 180. GCC AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 181. GCC AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GCC AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. GCC AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION AORTIC STENOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS AORTIC STENOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 206. G7 AORTIC STENOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. G7 AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. G7 AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 209. G7 AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 210. G7 AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 211. G7 AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 212. G7 AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 213. G7 AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 214. G7 AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. G7 AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. G7 AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 217. NATO AORTIC STENOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. NATO AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. NATO AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 220. NATO AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 221. NATO AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 222. NATO AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 223. NATO AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 224. NATO AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 225. NATO AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 226. NATO AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. NATO AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL AORTIC STENOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES AORTIC STENOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA AORTIC STENOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA AORTIC STENOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA AORTIC STENOSIS MARKET SIZE, BY TRANSCATHETER AORTIC VALVE REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA AORTIC STENOSIS MARKET SIZE, BY TRANSAPICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA AORTIC STENOSIS MARKET SIZE, BY TRANSFEMORAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA AORTIC STENOSIS MARKET SIZE, BY VALVE MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA AORTIC STENOSIS MARKET SIZE, BY BIOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA AORTIC STENOSIS MARKET SIZE, BY MECHANICAL, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA AORTIC STENOSIS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA AORTIC STENOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA AORTIC STENOSIS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)